fig3

Figure 3. Correlation between Phospho-TCTP expression and response to trastuzumab therapy. Representative images of the immunohistochemical staining of phospho-TCTP in HER2 + BC patients (A) responsive and (B) non-responsive to trastuzumab. From Lucibello et al. “Phospho-TCTP as a therapeutic target of dihydroartemisinin for aggressive breast cancer cells”. Oncotarget, 2015 [Figure 6]^[19]. BC: Breast cancers; HER2: human epidermal growth factor receptor-2; TCTP: translationally controlled tumor protein.